ARWR Stock Summary and Trading Ideas (Arrowhead Pharmaceuticals | NASDAQ:ARWR)

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.

Arrowhead Pharmaceuticals trades on the NASDAQ stock market under the symbol ARWR.

As of March 9, 2026, ARWR stock price declined to $57.97 with 329,102 million shares trading.

ARWR has a beta of 2.74, meaning it tends to be more sensitive to market movements. ARWR has a correlation of 0.43 to the broad based SPY ETF.

ARWR has a market cap of $8.12 billion. This is considered a Mid Cap stock.

Last quarter Arrowhead Pharmaceuticals reported $264 million in Revenue and $.22 earnings per share. This beat revenue expectation by $7 million and exceeded earnings estimates by $.20.

In the last 3 years, ARWR traded as high as $76.76 and as low as $9.57.

The top ETF exchange traded funds that ARWR belongs to (by Net Assets): VTI, IJH, VB, IWM, VBK.

ARWR has outperformed the market in the last year with a return of +228.1%, while the SPY ETF gained +17.3%. However, in the most recent history, ARWR shares have underperformed the stock market with its stock returning -5.6% in the last 3 month period and -8.8% for the last 2 week period, while SPY has returned -2.8% and -3.6%, respectively.

ARWR support price is $57.75 and resistance is $61.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARWR shares will trade within this expected range on the day.